Table 2.

Multivariable analyses for overall mortality—entire cohort.

Cohort (n) Variable (Reference Group)	Risk Ratio	p-Value
All KIR-L States (n = 775)
ATG—all dose levels (ref.: no ATG)	0.71	0.014
unrelated donor (ref.: related donor)	1.45	0.015
disease status—int./advanced (ref.: early)	2.17	<0.0001
HLA mismatch (ref.: HLA match)	1.42	0.008
donor age (continuous, per year)	1.01	0.020
MTX-based GVHD prophylaxis (ref.: no MTX)	0.78	0.014
ATG—lower dose levels (ref.: no ATG; n = 660)	0.61	0.001
C1/1 KIR Ligand State (n = 291)
ATG—all dose levels (ref.: no ATG)	0.50	0.003
disease status—int./advanced (ref.: early)	2.00	0.0001
unrelated donor (ref.: related donor)	1.84	0.008
ATG—lower dose levels (ref.: no ATG; n = 237)	0.42	0.001
C1/2 KIR Ligand State (n = 363)
ATG—all dose levels (ref.: no ATG)	0.70	0.065
disease status—int./advanced (ref.: early)	2.04	<0.0001
unrelated donor (ref.: related donor)	1.55	0.034
sex mismatch—female to male (ref.: all other)	1.38	0.038
MTX-based GVHD prophylaxis (ref.: no MTX)	0.63	0.008
RIC Regimen (Ref.: myeloablative)	0.71	0.039
ATG—lower dose levels (ref.: no ATG; n = 322)	0.60	0.018
C2/2 KIR Ligand State (n = 121) Inclusion of all ATG dose levels (121)
ATG—all dose levels (ref.: no ATG)	1.50	0.17
disease status—int./advanced (ref.: early)	3.46	<0.0001
donor age (continuous, per year)	1.03	0.011
ATG—lower dose levels (ref.: no ATG; n = 101)	1.69	0.15